The rate of resistance to third-generation cephalosporins (3GC) in gram-negative nosocomial infections is increasing worldwide, forcing clinicians to adopt alternative treatment to face multi-drug resistant strains. Rapid confirmation of 3GC resistance remains nowadays a priority for microbiologists. Today, microbiological susceptibility cultures are largely used because of their simplicity and low cost. However, cultures are time-consuming, providing resistance profiles in up to 4 or 5 days. Although presented as interesting alternatives, biochemical colorimetric tests could be in some case difficult to interpret because they are based on a subjective reading of a colour change. To circumvent that issue, Coris BioConcept is currently developing a new diagnostic tool to measure 3GC hydrolysis activity on bacterial colonies or on positive blood culture broths. This new assay, based on a recently-patented original method, delivers an objective digital result compared to phenotypic colorimetric assays. Used as a frontline test on gram-negative culture, it is foreseen as the ideal tool to accelerate decision on the implementation of infection control plans. Coris BioConcept is a Belgian company developing and manufacturing in-vitro diagnostic tests. With this new product in the pipeline, Coris BioConcept is offering an additional solution to its already existing RESIST products (immunochromatographic tests for the precise determination of carbapenemase-expressing organisms), and tightening its position as a key player in the field of antimicrobial resistance diagnosis.\nwww.corisbio.com<\/link>\n
\nSupplier:<\/strong> Coris Bioconcept
\nWebsite:<\/strong> <\/a><\/p>\n